Things are moving on at Sanofi in the fight against Covid! This Friday March 12, 2021, the French laboratory issued a release stating they are launching human clinical trials of their second vaccine. A solution developed by Sanofi and American company Translate Bio as they "initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate".
First and second phase clinical trials aiming at checking the vaccine is not dangerous and assessing its effetciveness. The clinical trial is said to include 415 volunteers and results are expected for the third quarter of 2021, in order to initiate a third phase including a greater number of volunteers.
But do not expect marketing authorization in 2021. This Sunday February 14, the French laboratory director general, Paul Hudson, announced in an interview with Journal du Dimanche the pharmaceutical group’s second vaccine – being developed in partnership with American company Translate Bio – will not be released in 2021 as first expected.
But this vaccine “could be of use at a later stage all the more if the fight against variants was to continue” he explained. He detailed “this technology, developed with the biotech Translate Bio, with which we have been associated since 2018, has shown the production of high concentrations of antibodies in preclinical studies”.
This is a vaccine that uses – like Pfizer or Moderna – the mRNA technology. Clinical trials are to start this quarter. Please also note another vaccine designed by Sanofi – in partnership with GSK – has been delayed and is to be issued by the end of 2021 – if everything goes as scheduled. In the meantime, the French group has also stated that they will help competitor Pfizer manufacture more doses of their vaccine by rallying several production chains in Europe.